Apr 20, 2021 09:23 JST

Source: Eisai

Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease
Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy

Lecanemab Phase 3 Clarity AD Clinical Trial Completed Enrollment

TOKYO, Apr 20, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with Lecanemab, an Anti-Abeta Protofibril Antibody, in the peer-reviewed journal Alzheimer's Research and Therapy. The manuscript describes results from Study 201, a Phase 2b proof- of-concept clinical trial that explored the impact of treatment with lecanemab (BAN2401) on reducing brain amyloid beta (Abeta) and clinical decline. The manuscript concluded that the pre-specified analysis showed consistent reduction of clinical decline across several clinical and biomarker endpoints at the highest doses, which the Phase 3 clinical trial Clarity AD aims to confirm. The results of Study 201 were presented at the Alzheimer's Association International Conference and Clinical Trials on Alzheimer's Disease in 2018.

The lecanemab Clarity AD Phase 3 clinical trial completed enrollment last month with 1,795 symptomatic patients with early Alzheimer's disease (AD). Clarity AD is a placebo-controlled, double-blind, parallel-group, 18-month study with an open-label extension phase designed to confirm safety and efficacy of lecanemab in subjects with early AD. Additionally, the Phase 3 AHEAD 3-45 clinical study is currently exploring lecanemab in individuals with preclinical AD, defined as patients that are clinically asymptomatic, but have intermediate or elevated brain Aβ levels.

"Amyloid beta aggregates are thought to be more toxic than monomers, and we hypothesized that reducing these could represent an effective treatment approach in early stages of Alzheimer's disease," said Jeffrey Cummings, M.D., ScD, lecanemab manuscript author and director at the Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas. "These results from lecanemab's Phase 2b clinical trial are encouraging and the scientific community is looking forward to learning more in the Phase 3 studies, Clarity AD and AHEAD 3-45, currently underway."

"These supportive findings from the lecanemab Phase 2b study and the initiation of two Phase 3 studies are exciting for the field and provide the opportunity to further explore the key role of the amyloid beta pathway in the pathophysiology of Alzheimer's disease," said Michael Irizarry, M.D., Vice President, Deputy Chief Clinical Officer, Neurology Business Group, Eisai Inc. "Eisai's precision pipeline approach envisions an Alzheimer's disease treatment paradigm based on a person's pathophysiological biomarker profile along the disease continuum. We are working to advance lecanemab and our other targeted investigational compounds as quickly as possible in our commitment to bringing solutions to patients and their families."

For more information, visit https://www.eisai.com/news/2021/pdf/enews202128pdf.pdf.

Source: Eisai
Sectors: BioTech

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
June 15 2021 08:00 JST
 
Eisai Receives Special Prize at Platinum Career Award 2021
June 09 2021 12:44 JST
 
Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)
June 09 2021 10:31 JST
 
Biogen and Eisai launch initiatives to help patients with Alzheimer's disease access ADUHELM
June 08 2021 13:09 JST
 
FDA grants accelerated approval for ADUHELM as the first and only Alzheimer's disease treatment to address a defining pathology of the disease
June 08 2021 08:47 JST
 
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib
June 08 2021 07:19 JST
 
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
May 31 2021 17:54 JST
 
Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting
May 20 2021 08:36 JST
 
Anticancer Agent "Remitoro Intravenous Drip Infusion 300 microgram" (Denileukin Diftitox (Genetical Recombination)) Launched in Japan
May 19 2021 11:27 JST
 
Eisai and National Cancer Center Commence Joint Research and Development Project
May 14 2021 16:48 JST
 
More Press release >>

Latest Press Release


More Latest Release >>